PNC-27 30mg
p53-Derived Peptide with Selective Cancer Cell Membrane Disruption
PNC-27 is a peptide containing a p53 sequence that selectively disrupts the membranes of cancer cells expressing HDM-2 on their surface while leaving normal cells unaffected, representing a novel mechanism of anticancer peptide research.
p53-Derived Peptide with Selective Cancer Cell Membrane Disruption
PNC-27 incorporates a p53 activation domain fused to a membrane-penetrating sequence. It binds HDM-2 expressed on cancer cell membranes, creating pores that lead to selective cancer cell necrosis in preclinical models across multiple tumor types.
As one of the most studied compounds in the longevity research space, PNC-27 has attracted sustained scientific interest across Anticancer peptide research, HDM-2 biology studies, p53 pathway research. Peer-reviewed evidence indicates that selectively kills HDM-2 expressing cancer cells, which has positioned PNC-27 as a reference standard for researchers exploring anticancer peptide research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
PNC-27 Documented Benefits: 3 Documented Mechanisms
Cancer Cell Selectivity
Binds HDM-2 on cancer cell surfaces, sparing normal cells from membrane disruption.
Novel Mechanism
Direct membrane disruption distinct from conventional apoptosis inducers.
Broad Tumor Activity
Shown effective against breast, pancreatic, and leukemia cell lines in vitro.
How PNC-27 Works: Molecular Mechanism & Pathway
p53 activation domain fused to membrane-penetrating sequence; binds surface HDM-2 on cancer cells, inserting into the membrane and forming lethal pores.
The 3 primary research pathways identified for PNC-27 — Cancer Cell Selectivity, Novel Mechanism, Broad Tumor Activity — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that effective against multiple cancer cell lines in vitro, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, PNC-27's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
PNC-27 is routinely studied alongside Epitalon and NAD+ in longevity-focused compound panels. Researchers investigating anticancer peptide research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that normal cell viability preserved in studies has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All PNC-27 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Selectively kills HDM-2 expressing cancer cells
- Effective against multiple cancer cell lines in vitro
- Normal cell viability preserved in studies
Ideal For
- Anticancer peptide research
- HDM-2 biology studies
- p53 pathway research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on PNC-27. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Selectively kills HDM-2 expressing cancer cells
Effective against multiple cancer cell lines in vitro
Normal cell viability preserved in studies
Third-Party Verified Every Batch
Each vial of PNC-27 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
